Rapoport L M, Bezrukov E A, Kondrashina A V
The Department of Urology of Medical Faculty, I.M. Sechenov First Moscow State Medical University of Minzdrav of Russia.
Urologiia. 2016 Feb(1):58-61.
The relevance of drug treatment for prostate cancer increases with the number of patients who develop castration resistance. Currently, no unified treatment regimen for castration-resistant prostate cancer exists, but the standard treatment for these patients is continuous androgen deprivation therapy. This paper presents the experience of concomitant use of abiraterone acetate and triptorelin in patients with castration-resistant prostate cancer. Ten patients with disease duration of 1.5 to 18 years and established castration resistance are currently being followed up. Nine of ten patients have long-term bone metastases, one patient has visceral metastases. The combination therapy produced a significant PSA decrease in nine patients and regression of bone lesions in two patients.
随着去势抵抗性前列腺癌患者数量的增加，药物治疗前列腺癌的相关性也随之提高。目前，对于去势抵抗性前列腺癌尚无统一的治疗方案，但这些患者的标准治疗是持续雄激素剥夺治疗。本文介绍了醋酸阿比特龙与曲普瑞林联合应用于去势抵抗性前列腺癌患者的经验。目前正在对10例疾病持续时间为1.5至18年且已确立去势抵抗的患者进行随访。10例患者中有9例有长期骨转移，1例有内脏转移。联合治疗使9例患者的前列腺特异性抗原（PSA）显著下降，2例患者的骨病变有所消退。
